[PDF] Top 20 LA DIDÁCTICA EN MATEMÁTICAS EN LA RESOLUCIÓN DE PROBLEMAS EN LOS ESTUDIANTES DE BÁSICA SUPERIOR

... with potential to cause bleeding). A total of 125 patients were randomized to receive once-daily doses of apixaban 5 mg (n = 32), 10 mg (n = 30), 20 mg (n = 33), or placebo (n = 30) in a double-blind manner ... See full document

... Abstract: Patients with cancer have a 6–7-fold higher risk of venous thromboembolism (VTE) as compared with non-cancer ...the prevention and treatment of VTE is the ... See full document

... VTE Cancer and SELECT-D, as well as the meta-analyses, observed increased bleeding events, including numerous gastrointestinal (GI) bleeds, in the DOAC ...for treatment of VTE, 32 as well as trials ... See full document

... surgical patients at moderate risk, the recommended dose is 20 mg (2000 units) about two hours before surgery then 20 mg (2000 units) every 24 ...High-risk patients (such as those undergoing orthopedic ... See full document

... initial treatment of DVT, as effective as UFH for treatment of PE, and more effective than LMWH for prevention of VTE following orthopedic ...in patients randomized to fondaparinux in the ... See full document

... CAT treatment was primarily by means of oral ...the patients. LMWH was already used for CAT treatment, but mainly during the first week after VTE diagnosis, and then replaced by ...secondary ... See full document

... Three Phase III trials have been designed to explore the efficacy and safety of apixaban for the prevention of throm- boembolism after major orthopedic surgery (ADVANCE program). The primary efficacy outcome of ... See full document

... many patients with CAT are switched to, or even initiated on, a VKA [22, 23], possibly because of a preference for oral over injectable therapies [25] or for cost ...in patients treated with rivaroxaban or ... See full document

... a new class of anticoagulant drugs, designed to overcome the unmet needs of current ...both patients and physicians than heparins or VKAs, but apart these practical advantages of direct oral ... See full document

... a new FXa inhibitor with unique pharmacoki- netic characteristics: minimal renal clearance, minimal hepatic metabolism, and a long ...in patients with severe renal failure, a population with unmet ... See full document

... secondary prevention of arterial antithrombotic ...the prevention of the initiation and development of venous ...the prevention of venous thromboembolism (VTE), especially the ... See full document

... in patients with renal insufficiency. The trials for both the treatment and secondary prevention of VTE included patients with some degree of renal ...excluded patients with CrCl of 30 ... See full document

... oral anticoagulants (NOACs) that appear to offer new hope for patients needing anticoagulant ...These new medications offer the benefit of predictable oral anticoagulation with less drug-drug ... See full document

... available clinical evidence for each agent. The newer parenteral anticoagulant, fondaparinux, is now also licensed for VTE prophylaxis in surgical patients and the treatment of acute DVT; clinical ... See full document

... sinus venous thrombosis and hepatic/portal/splanchnic vein thrombosis was objec- tively documented using computed tomography angiography, magnetic resonance or magnetic resonance ... See full document

... different treatment algorithms and dosing regimens by providing more data on the epidemiology, pharmacol- ogy, and bleeding complications of the disease in Asian patients which may differ significantly from ... See full document

... Abstract: Venous thromboembolism (VTE) is a multifactorial disease manifesting as either deep vein thrombosis or pulmonary ...those patients and improve their quality of life and ... See full document

... ‘no treatment’ situation, the logical choice would be to use a geometric scale (relative reduc- tion of outcome rates upon relative ...standard treatment, the starting point is the observed incidence on ... See full document

... Background: Cancer and its therapies increase the risk of venous ...to patients without cancer, patients with cancer anticoagulated for venous thromboembolism are ... See full document

... In a case-control study in women aged 45–64 years, the relative risk of idiopathic VTE in HRT users showed a signifi- cant association with APC resistance (OR 4.06), low antithrom- bin levels (OR 3.33), low protein C ... See full document